We are live on ! Find out more
PRVL

Prevail Therapeutics Inc. Common Stock
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

Back to rankings

93 hedge funds and large institutions have $648M invested in Prevail Therapeutics Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 16 increasing their positions, 27 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more capital invested

Capital invested by funds: $302M → $648M (+$346M)

71% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 24

22% more funds holding

Funds holding: 76 → 93 (+17)

41% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 27

77% less call options, than puts

Call options by funds: $3.68M | Put options by funds: $15.8M

Holders
93
Holders Change
+17
Holders Change %
+22.37%
% of All Funds
1.65%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
41
Increased
16
Reduced
27
Closed
24
Calls
$3.68M
Puts
$15.8M
Net Calls
-$12.1M
Net Calls Change
-$12.1M

Top Buyers

Rank Fund Capital Flow
1
AAM
Alpine Associates Management
Florida
+$10.9M
2
TAL
TIG Advisors LLC
New York
+$8.99M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$7.55M
4
Millennium Management
Millennium Management
New York
+$6.64M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$3.52M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$19.5M
2
HighTower Advisors
HighTower Advisors
Illinois
-$11.5M
3
BlackRock
BlackRock
New York
-$9.81M
4
Morgan Stanley
Morgan Stanley
New York
-$7.86M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
EPM
26
Equitec Proprietary Markets
Illinois
$2.83M +$1.56M +122,800 New
WAM
27
Weiss Asset Management
Massachusetts
$2.6M +$1.43M +112,827 New
Qube Research & Technologies (QRT)
28
Qube Research & Technologies (QRT)
United Kingdom
$2.46M +$1.35M +106,544 New
VI
29
Vestcor Inc
New Brunswick, Canada
$2.31M +$1.27M +100,000 New
CS
30
Credit Suisse
Switzerland
$2.23M +$1.22M +96,567 New
WIC
31
Water Island Capital
New York
$2.18M +$1.2M +94,608 New
LP
32
LMR Partners
United Kingdom
$1.85M +$1.01M +80,000 New
DCM
33
DAFNA Capital Management
California
$1.73M – – –
YCM
34
Yakira Capital Management
Connecticut
$1.71M +$939K +74,056 New
AC
35
Aristides Capital
Kentucky
$1.61M +$887K +70,000 New
HM
36
Harvest Management
New York
$1.61M +$887K +70,000 New
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
$1.23M +$675K +53,276 New
AS
38
Altshuler Shaham
Israel
$1.2M – – –
N
39
Nuveen
North Carolina
$1.1M -$173K -13,686 -14%
Squarepoint
40
Squarepoint
New York
$1M -$351K -27,709 -39%
CL
41
CSS LLC
Illinois
$896K +$492K +38,843 New
GCP
42
GSA Capital Partners
United Kingdom
$824K -$219K -17,301 -33%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$773K -$1.21M -95,826 -74%
Charles Schwab
44
Charles Schwab
California
$768K – – –
Wells Fargo
45
Wells Fargo
California
$749K +$291K +22,979 +242%
California Public Employees Retirement System
46
California Public Employees Retirement System
California
$745K -$7.6K -600 -2%
WMSA
47
Weiss Multi-Strategy Advisers
New York
$717K +$394K +31,061 New
GI
48
GAMCO Investors
Connecticut
$657K +$361K +28,500 New
Los Angeles Capital Management
49
Los Angeles Capital Management
California
$593K +$47.8K +3,772 +17%
VEA
50
Virtus ETF Advisers
New York
$544K +$48.5K +3,828 +19%
1
2
3 4 5

PRVL Hedge Fund Activity: Q4 2020 in Review

93 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q4 2020, worth a combined $648M — up 115% from $302M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new PRVL positions and 24 closed out — a net gain of 17 holders — while 16 added to existing stakes and 27 trimmed.

The largest buyer was Alpine Associates Management, opening a new position worth an estimated $10.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $19.5M sold.

  • 93 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q4 2020, up from 76 in Q3 2020.
  • Funds reported $648M of Prevail Therapeutics Inc. Common Stock stock for Q4 2020, up 115% quarter-over-quarter.
  • 41 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q4 2020 and 24 closed out, a net change of +17 holders.
  • The largest Prevail Therapeutics Inc. Common Stock buyer in Q4 2020 was Alpine Associates Management, an estimated $10.9M added.
  • The largest Prevail Therapeutics Inc. Common Stock seller in Q4 2020 was RA Capital Management, an estimated $19.5M sold.

Based on aggregated 13F filings for Q4 2020.